Caliway Biopharmaceuticals (TWSE: 6919) presented preclinical data on its drug candidate CBL-514 combined with GLP-1 receptor-based weight-loss therapies at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE